Figure 5.

Drug potency of active AH‐7921 series compounds. HT1080 hMOR cells are treated with 100 μmol L⁻¹ FSK only, or FSK with 0.01 μmol L⁻¹ (low), 0.1 μmol L⁻¹ (mid), 1 μmol L⁻¹ (high) of the indicated compound, and high concentration dose of the compound with 10 μmol L⁻¹ NLX. Each treatment dose was performed in triplicate (n = 2; data from representative experiment shown) and data were analyzed using one‐way ANOVA with Dunnett multiple comparison test and FSK only as standard. *P < 0.05